

DETAILED ACTION

Allowable Subject Matter

Claims 64, 94-100, 103, 106-109, 114 and 118 are allowed.

Claims 94-100, 103, 106-109, 114 and 118 directed to an allowable product.

Pursuant to the procedures set forth in MPEP § 821.04(B), claim 64, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, is hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, **the restriction requirement as set forth in the Office action mailed on 4/07/2005 is hereby withdrawn.** In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Arnold Krumholz on August 3, 2009.

The application has been amended as follows:

In claim 108, line 3, delete "solid".

In claim 108, line 3, delete "selection"

In claim 108, line 3, insert "selected" between "drug" and "from".

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: US Patent's 7,070,808 and 7,150,881 were used to reject the claims under an Obviousness-type Double Patenting rejection. US Patent's 7,070,808 and 7,150,881 disclose an adhesive composition of the instant claims, however a crosslinking agent is also required. The present invention differs in that the crosslinking agent is not required. Applicant has overcome the rejections by filing terminal disclaimers on 4/18/2008.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIELLE SULLIVAN whose telephone number is (571)270-3285. The examiner can normally be reached on 7:30 AM - 5:00 PM Mon-Thur EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/730,561
Art Unit: 1616

Page 5

/Johann R. Richter/
Supervisory Patent Examiner, Art Unit 1616